Product Description: Elsibucol is a VCAM1 inhibitor for the study of organ transplant rejection. Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. Elsibucol lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C35H54O4S2
References: [1]Dussault S, et al. Elsibucol inhibits atherosclerosis following arterial injury: multifunctional effects on cholesterol levels, oxidative stress and inflammation[J]. Atherosclerosis, 2014, 237(1): 194-199./[2]Murata S, et al. Effects of AGI-1096, a novel antioxidant compound with anti-inflammatory and antiproliferative properties, on rodent allograft arteriosclerosis[J]. Transplantation, 2004, 77(10): 1494-1500./[3]First M R, et al. New drugs to improve transplant outcomes[J]. Transplantation, 2004, 77(9): S88-S92.
CAS Number: 216167-95-2
Molecular Weight: 602.93
Compound Purity: 99.35
Research Area: Inflammation/Immunology; Cardiovascular Disease
Solubility: DMSO : 25 mg/mL (ultrasonic)
Target: Integrin;Transmembrane Glycoprotein
English
Deutsch
